Floatz logo

TRASTUZUMAB

Stage III Colon Cancer

IFOM ETS - The AIRC Institute of Molecular Oncologymonoclonal_antibodyPhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Stage III Colon Cancer cohort.

Asset / SponsorPhaseRating
Encorafenib
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 3BB
Binimetinib
AIO-Studien-gGmbH
Phase 3BB
Avelumab
Royal Marsden NHS Foundation Trust
Phase 3CCC

Same molecule, other indications

TRASTUZUMAB is also rated in:

breast carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
inflammatory breast carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
HER2/Neu PositiveDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →